keyword
MENU ▼
Read by QxMD icon Read
search

molecular thyroid cancer

keyword
https://www.readbyqxmd.com/read/28219937/a-meta-analysis-of-prognostic-roles-of-molecular-markers-in-papillary-thyroid-carcinoma
#1
Huy Gia Vuong, Uyen N P Duong, Ahmed M A Altibi, Hanh T T Ngo, Thong Quang Pham, Hung Minh Tran, Greta Gandolfi, Lewis Hassell
The prognostic role of molecular markers in papillary thyroid carcinoma (PTC) is a matter of ongoing debate. The aim of our study is to investigate the impact of RAS, BRAF, TERT promoter mutations and RET/PTC rearrangements on prognosis of PTC patients. We performed a search in four electronic databases: PubMed, Scopus, Web of Science and Virtual Health Library (VHL). Data of hazard ratio (HR) and its 95% confidence interval (CI) for Disease-specific survival (DSS) and Disease-free survival (DFS) were directly obtained from original papers or indirectly estimated from Kaplan Meier curve (KMC)...
February 20, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28218046/thyroid-transcription-factor-1-expression-is-associated-with-outcome-of-patients-with-non-squamous-non-small-cell-lung-cancer-treated-with-pemetrexed-based-chemotherapy
#2
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28216675/extracellular-superoxide-dismutase-expression-in-papillary-thyroid-cancer-mesenchymal-stem-stromal-cells-modulates-cancer-cell-growth-and-migration
#3
Alessia Parascandolo, Francesca Rappa, Francesco Cappello, Jaehyup Kim, David A Cantu, Herbert Chen, Gianluigi Mazzoccoli, Peiman Hematti, Maria Domenica Castellone, Marco Salvatore, Mikko O Laukkanen
Tumor stroma-secreted growth factors, cytokines, and reactive oxygen species (ROS) influence tumor development from early stages to the metastasis phase. Previous studies have demonstrated downregulation of ROS-producing extracellular superoxide dismutase (SOD3) in thyroid cancer cell lines although according to recent data, the expression of SOD3 at physiological levels stimulates normal and cancer cell proliferation. Therefore, to analyze the expression of SOD3 in tumor stroma, we characterized stromal cells from the thyroid...
February 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28202213/recent-developments-in-the-pathology-of-thyroid-cancer
#4
D N Poller, S J Johnson
The histopathological features of thyroid cancers can be used to risk stratify patients, allowing prognostication and treatment decisions. A detailed accurate histological assessment by experienced pathologists working within a multidisciplinary context is crucial. Experience is also essential for interpretation of preoperative thyroid cytology specimens, which can be challenging. There is now more international harmonisation of numerical reporting systems for thyroid cytology. Understanding of the molecular basis of thyroid cancer has increased dramatically in recent years...
February 12, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28192645/cytological-molecular-and-clinical-features-of-noninvasive-follicular-thyroid-neoplasm-with-papillary-like-nuclear-features-versus-invasive-forms-of-follicular-variant-of-papillary-thyroid-carcinoma
#5
Liena Zhao, Dora Dias-Santagata, Peter M Sadow, William C Faquin
BACKGROUND: The noninvasive follicular variant of papillary thyroid carcinoma (PTC) has an indolent clinical behavior in comparison with other PTCs, including the invasive follicular variant of papillary thyroid carcinoma (IFVPTC). Recently, the term noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was introduced to emphasize the low biological potential of these tumors. This study compares clinical, cytological, and molecular features of NIFTP and IFVPTC...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28192058/the-sodium-iodide-symporter-nis-molecular-physiology-and-preclinical-and-clinical-applications
#6
Silvia Ravera, Andrea Reyna-Neyra, Giuseppe Ferrandino, L Mario Amzel, Nancy Carrasco
Active iodide (I(-)) transport in both the thyroid and some extrathyroidal tissues is mediated by the Na(+)/I(-) symporter (NIS). In the thyroid, NIS-mediated I(-) uptake plays a pivotal role in thyroid hormone (TH) biosynthesis. THs are key during embryonic and postembryonic development and critical for cell metabolism at all stages of life. The molecular characterization of NIS in 1996 and the use of radioactive I(-) isotopes have led to significant advances in the diagnosis and treatment of thyroid cancer and provide the molecular basis for studies aimed at extending the use of radioiodide treatment in extrathyroidal malignancies...
February 10, 2017: Annual Review of Physiology
https://www.readbyqxmd.com/read/28187755/long-noncoding-rna-papillary-thyroid-carcinoma-susceptibility-candidate-3-ptcsc3-inhibits-proliferation-and-invasion-of-glioma-cells-by-suppressing-the-wnt-%C3%AE-catenin-signaling-pathway
#7
Shujun Xia, Ri Ji, Weiwei Zhan
BACKGROUND: The dysregulation of long noncoding RNAs (lncRNAs) has been identified in a variety of cancers. An increasing number of studies have found the critical role of lncRNAs in the regulation of cellular processes, such as proliferation, invasion and differentiation. Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) is a novel lncRNA that was primarily detected in papillary thyroid carcinoma. However, the biological function and molecular mechanism of lncRNA PTCSC3 in glioma are still unknown...
February 10, 2017: BMC Neurology
https://www.readbyqxmd.com/read/28185633/expression-profile-of-biomarkers-altered-in-papillary-and-anaplastic-thyroid-carcinoma-contribution-of-tunisian-patients
#8
Asma Fourati, Olfa El Amine, Wided Ben Ayoub, Imen Cherni, Aida Goucha, Michèle Véronique El May, Amor Gamoudi, Ahmed El May
AIMS: The objective of this study was to compare the protein expression profile between well-differentiated (papillary) and undifferentiated (anaplastic) thyroid carcinoma in Tunisian patients. METHODS: This first Tunisian retrospective study concerned data of 38 thyroid cancer cases (19 papillary carcinoma PTC and 19 anaplastic carcinoma ATC) collected at Salah Azaiez Institute of Tunisia. Immunohistochemistry was used to evaluate tumor expression of different molecular markers (p53, Ki67, E-cadherin, cyclin D1, bcl2, S100 and Her-2)...
February 6, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28181854/effects-of-coexistent-brafv600e-and-tert-promoter-mutations-on-poor-clinical-outcomes-in-papillary-thyroid-cancer-a-meta-analysis
#9
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park
BACKGROUND: Presence of a TERT promoter mutation has been suggested as a potential prognostic marker for thyroid cancer and a synergistic association with the BRAFV600E mutation has been demonstrated. The aim of this study was to verify the role of this genetic duet in papillary thyroid cancer (PTC). METHODS: Studies of the association of BRAFV600E and TERT promoter mutations with clinicopathological features, recurrence, or PTC-related mortality were included from PubMed and Embase databases (inception to September 2016)...
February 9, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28178124/anaplastic-thyroid-carcinoma-and-foscarnet-use-in-a-multitarget-treatment-documented-by-18f-fdg-pet-ct-a-case-report
#10
Elisa Giannetta, Andrea M Isidori, Cosimo Durante, Cira Di Gioia, Flavia Longo, Vincenzo Tombolini, Nadia Bulzonetti, Chiara Graziadio, Riccardo Pofi, Daniele Gianfrilli, Antonella Verrienti, Raffaella Carletti, Sebastiano Filetti, Andrea Lenzi, Alberto Baroli
RATIONALE: The case reported the rapid remission of disease recurrence achieved adding foscarnet, a DNA polymerase inhibitor that interacts with fibroblast growth factor 2, to low molecular weight heparin and sunitinib for the first time in a patient with an anaplastic thyroid cancer (ATC). PATIENT CONCERNS: A 65-year-old woman with a multinodular goiter referred for a rapid enlargement of a nodule. Histological examination revealed an ATC with a little area of papillary thyroid cancer (PTC)...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28175931/determining-patient-preferences-for-indeterminate-thyroid-nodules-observation-surgery-or-molecular-tests
#11
Daniel Joonil Lee, Jason J Xu, Dale H Brown, Ralph W Gilbert, Patrick J Gullane, Jonathan C Irish, Lorne E Rotstein, David P Goldstein, John R de Almeida
BACKGROUND: Gene-expression classifiers (GEC) and genetic mutation panels (GMP) have been shown to improve preoperative diagnostic evaluations of indeterminate thyroid nodules. Despite the improvement, uncertainty regarding the proper management exists. Patient preferences may better inform the management of these indeterminate thyroid nodules. METHODS: Hypothetical scenarios were administered to two groups of patients: those with previous FNA-confirmed indeterminate thyroid nodules (Group A, n = 50) and those presenting to a general otolaryngology clinic for other reasons (Group B, n = 50)...
February 7, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28152275/qualifiers-of-atypia-in-the-cytologic-diagnosis-of-thyroid-nodules-are-associated-with-different-afirma-gene-expression-classifier-results-and-clinical-outcomes
#12
Sylvan C Baca, Kristine S Wong, Kyle C Strickland, Howard T Heller, Matthew I Kim, Justine A Barletta, Edmund S Cibas, Jeffrey F Krane, Ellen Marqusee, Trevor E Angell
BACKGROUND: Thyroid nodules with atypia of undetermined significance (AUS) on fine-needle aspiration (FNA) have a low risk of malignancy that appears to vary based on specific features described in the AUS diagnosis. The Afirma gene expression classifier (GEC) is a molecular test designed to improve preoperative risk stratification of thyroid nodules, but its performance for different patterns of AUS has not been defined. The objective of this study was to assess GEC results and clinical outcomes in AUS nodules with architectural atypia (AUS-A), cytologic atypia (AUS-C) or both (AUS-C/A)...
February 2, 2017: Cancer
https://www.readbyqxmd.com/read/28150875/atp2a3-gene-as-an-important-player-for-resveratrol-anticancer-activity-in-breast-cancer-cells
#13
Eduardo Izquierdo-Torres, Gabriela Rodríguez, Iván Meneses-Morales, Angel Zarain-Herzberg
The Ca(2+) -ATPases from the Sarco/endoplasmic reticulum (SERCA) are fundamental for maintaining intracellular [Ca(2+) ] homeostasis by pumping Ca(2+) into the endoplasmic reticulum (ER) of eukaryotic cells. SERCA enzymes are encoded by three different genes (ATP2A1-3), whose expression occurs in a tissue and development stage-specific manner. It has been reported alterations in the expression of SERCA2 and SERCA3 pumps in different types of cancer: oral, lung, colon, stomach, central nervous system, thyroid, breast, and prostate...
February 2, 2017: Molecular Carcinogenesis
https://www.readbyqxmd.com/read/28141684/treatment-and-surveillance-of-advanced-metastatic-iodine-resistant-differentiated-thyroid-cancer
#14
Eiman Y Ibrahim, Naifa L Busaidy
PURPOSE OF REVIEW: This review will focus on the management and treatment of metastatic thyroid cancer that is radioactive iodine refractory and review the new drugs and their mechanism of actions as well as their adverse events. RECENT FINDINGS: Until recently, there were no efficacious therapeutic modalities for these patients. With advancement in knowledge and research of the molecular aberrations and oncogenic mutations in thyroid cancer as well as further understanding the role of angiogenesis in tumor growth molecular pathogenesis, novel targeted therapies are available for these patients...
March 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28137980/nelfinavir-inhibits-proliferation-and-induces-dna-damage-in-thyroid-cancer-cells
#15
Kirk Jensen, Athanasios D Bikas, Aneeta Patel, Yevgeniya Kushchayeva, John Costello, Dennis McDaniel, Kenneth Burman, Vasily Vasko
The HIV protease inhibitor Nelfinavir (NFV) inhibits PI3K/AKT and MAPK/ERK signaling pathways, emerging targets in thyroid cancers. We examined the effects of NFV on cancer cells that derived from follicular (FTC), papillary (PTC) and anaplastic (ATC) thyroid cancers. NFV (1-20 μM) was tested in FTC133, BCPAP and SW1736 cell lines. The effects of NFV on cell proliferation were determined in vitro using real-time microscopy and by flow cytometry. DNA damage, apoptotic cell death, and expression of molecular markers of epithelial-mesenchymal transition (EMT) were determined by Western blot and real-time PCR...
January 30, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28131876/modulating-the-function-of-atp-binding-cassette-subfamily-g-member-2-abcg2-with-inhibitor-cabozantinib
#16
Guan-Nan Zhang, Yun-Kai Zhang, Yi-Jun Wang, Anna Maria Barbuti, Xi-Jun Zhu, Xin-Yue Yu, Ai-Wen Wen, John N D Wurpel, Zhe-Sheng Chen
Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2. Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma. In the present study, we evaluated the ability of cabozantinib to modulate the function of the ATP-binding cassette subfamily G member 2 (ABCG2) by sensitizing cells that are resistant to ABCG2 substrate antineoplastic drugs. We used a drug-selected resistant cell line H460/MX20 and three ABCG2 stable transfected cell lines ABCG2-482-R2, ABCG2-482-G2, and ABCG2-482-T7, which overexpress ABCG2...
January 25, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/28119454/selective-ablation-of-tumor-suppressors-in-parafollicular-c-cells-elicits-medullary-thyroid-carcinoma
#17
Hai Song, Chuwen Lin, Erica Yao, Kuan Zhang, Xiaoling Li, Qingzhe Wu, Pao-Tien Chuang
Among the four different types of thyroid cancer, treatment of medullary thyroid carcinoma poses a major challenge due to its propensity of early metastasis. To further investigate the molecular mechanisms of medullary thyroid carcinoma and discover candidates for targeted therapies, we developed a new mouse model of medullary thyroid carcinoma based on our CGRPCreER mouse line. This system enables gene manipulation in parafollicular C cells in the thyroid, the purported cells of origin of medullary thyroid carcinoma...
January 24, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/28111205/carcinogenic-risk-and-bisphenol-a-exposure-a-focus-on-molecular-aspects-in-endoderm-derived-glands
#18
Danila Cuomo, Immacolata Porreca, Gilda Cobellis, Roberta Tarallo, Giovanni Nassa, Geppino Falco, Antonio Nardone, Francesca Rizzo, Massimo Mallardo, Concetta Ambrosino
Epidemiological and experimental evidence associates the exposure to Bisphenol A with the increase of cancer risk in several organs, including prostate. BPA targets different pathways involved in carcinogenicity including the Nuclear Receptors (i.e. estrogen and androgen receptors), stress regulated proteins and, finally, epigenetic changes. Here, we analyse BPA-dependent carcinogenesis in endoderm-derived glands, thyroid, liver, pancreas and prostate focusing on cell signalling, DNA damage repair pathways and epigenetic modifications...
January 19, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28104680/evaluation-of-thyroseq-v2-performance-in-thyroid-nodules-with-indeterminate-cytology
#19
Pablo Valderrabano, Laila Khazai, Marino E Leon, Zachary J Thompson, Zhenjun Ma, Christine H Chung, Julie E Hallanger-Johnson, Kristen J Otto, Kara D Rogers, Barbara Centeno, Bryan McIver
ThyroSeq v2 claims high positive (PPV) and negative (NPV) predictive values in a wide range of pre-test risks of malignancy in indeterminate thyroid nodules (ITNs) (categories B-III and B-IV of the Bethesda system). We evaluated ThyroSeq v2 performance in a cohort of patients with ITNs seen at our Academic Cancer Center from September 2014 to April 2016, in light of the new diagnostic criteria for non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Our study included 182 patients (76% female) with 190 ITNs consecutively tested with ThyroSeq v2...
January 19, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28090518/clinical-characteristics-and-molecular-pathology-of-skull-ectopic-thyroid-cancer
#20
Longxing Cao, Zhongyong Wang, Jiawei Ma, Jinsheng Chen, Haojiang Zhu, Xiaohua Zhou, Qing Zhu, Jun Dong, Qing Lan, Qiang Huang
Thyroid cancer is very common, but skull ectopic thyroid cancer has not been reported in 50 years of literatures in foreign countries. There are only four cases of the skull ectopic thyroid cancer reported in more than 30 years of domestic literature including the cases in this report. This paper aims to investigate the clinical characteristics and possible molecular mechanisms of this rare disease. Five keywords of "thyroid gland", "ectopic thyroid", "thyroid cancer", "ectopic thyroid cancer" and "metastatic thyroid cancer" were included and 50 years of literatures in the PubMed-MEDLINE and Wanfang database were reviewed...
December 2016: Annals of Translational Medicine
keyword
keyword
104555
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"